Activity of plazomicin against carbapenem-intermediate or -resistant Escherichia coli isolates from the United States and international sites in relation to clonal background, resistance genes, co-resistance, and region.
Brian D JohnstonPaul ThurasStephen B PorterMelissa AnackerBrittany VonBankPaula Snippes VagnoneMedora WitwerMariana CastanheiraJames R JohnsonPublished in: The Journal of antimicrobial chemotherapy (2021)
The likely utility of plazomicin against CIR E. coli is high overall, but varies with region and multiple bacterial characteristics.